Welcome to our dedicated page for CHINA PHARMA HOLDINGS SEC filings (Ticker: CPHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHINA PHARMA HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHINA PHARMA HOLDINGS's regulatory disclosures and financial reporting.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, has entered into a Technology Transfer Agreement to acquire an invention patent for a Captopril microcapsule and its preparation method from an individual transferor. As consideration, the company values the transaction at $6.3 million, to be paid in shares of its common stock at $1.80 per share. In total, the company plans to issue 3,500,000 restricted common shares in connection with this technology transfer. The shares, if and when issued, will be offered in an offshore transaction to a non-U.S. person and will rely on Regulation S for exemption from registration under U.S. securities laws.
China Pharma Holdings (CPHI) called its Annual Meeting for December 30, 2025 to vote on three items: re‑elect three independent directors, authorize a reverse stock split of up to 1:20 at the Board’s discretion, and approve Amendment No. 3 to the Amended and Restated 2010 Long‑Term Incentive Plan to increase the share reserve by 500,000 shares (from 69,600 to 569,600).
The reverse split proposal is positioned as a tool to address potential NYSE American “low selling price” concerns; the Board notes prior reverse splits of 1‑for‑5 and 1‑for‑10 in 2024 and 2025. Fractional shares would be rounded up to a full share. Shares outstanding were 5,022,002 as of November 3, 2025, the record date. The proxy outlines standard voting mechanics, quorum (one‑third of outstanding), and recommends voting “FOR” all proposals. The filing also details 2024 audit fees of $125,000 and executive/director compensation, including CEO 2024 salary of $300,000 and outstanding restricted stock of 48,200 under the plan.
China Pharma Holdings (CPHI) reported Q3 2025 results showing continued losses amid tight liquidity. Revenue was $756,217, with a gross loss of $59,654 and net loss of $651,482 (loss per share $0.17). For the nine months, revenue was $2,918,271 and net loss was $1,965,421.
The company flagged substantial doubt about its ability to continue as a going concern. Cash and equivalents were $267,625 as of September 30, 2025, and current liabilities exceeded current assets by $4.3 million. Borrowings from the Chair/CEO totaled $1,413,340, supporting working capital.
Results improved year over year on lower depreciation and reduced inventory obsolescence, narrowing gross loss and operating loss. The company wrote off $13.7 million of long‑aged receivables in August 2025, sharply reducing the allowance. It also issued 1,760,000 shares for a patent asset valued at $2.446 million. A 1‑for‑10 reverse split took effect April 15, 2025; shares outstanding were 5,022,002 as of November 10, 2025.